ABOS ACUMEN PHARMACEUTICALS INC

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.  

To participate in the live conference call, please register using this  After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.   

The webcast audio will be available via this    

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at .

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit .

Investors:

Alex Braun

Media: 

 



EN
05/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ACUMEN PHARMACEUTICALS INC

 PRESS RELEASE

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Citi’s 2025 Biopharma Back to School Conference Date/Time: Fireside chat on Tuesday, September 2, 2025 at 3:15 p.m. ET Cantor Global Healthcare Conference 2025 Date/Time: Fireside chat on Frida...

 PRESS RELEASE

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results a...

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027 Company...

 PRESS RELEASE

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results...

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To part...

 PRESS RELEASE

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau2...

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025 NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overa...

 PRESS RELEASE

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collabo...

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer’s diseaseAgreement follows more than one year of engagement to assess...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch